{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:47Z","timestamp":1781650847736,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Council for Regenerative Medicine and Stem Cell Technologies","award":["11\/56333"],"award-info":[{"award-number":["11\/56333"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric dilated cardiomyopathy (PDCM) is a severe cardiovascular disorder characterized by ventricular systolic dysfunction, with heart transplantation as the gold standard therapy. Mesenchymal stromal cells (MSCs) have demonstrated promise for treating cardiomyopathy, but previous studies in pediatric patients have focused exclusively on autologous cells such as MSCs, while allogeneic MSCs with better results were studied only in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study \u201cA HEART-WISE\u201d is the first case reports to evaluate the safety and feasibility of intracoronary transplantation of allogeneic GMP-complierant Wharton\u2019s jelly-derived MSCs (WJ-MSCs) in PDCM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two pediatric patients with PDCM received a single intracoronary infusion of 1.5\u2009\u00d7\u200910\u2076 cells\/kg WJ-MSCs. Clinical evaluations included NYHA functional class, six-minute walk test (6MWT), N Terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac imaging over a 12-month follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both patients tolerated intracoronary WJ-MSC administration without serious adverse events related to the procedure. Patient 1 demonstrated marked improvements by 3 months (NYHA III to II, LVEF 33% to 48%, 6MWT 300 to 373\u00a0m, NT-proBNP 3502 to 1734 pg\/mL) but passed away at 6 months follow-up due to a viral infection. Patient 2 had a persistently reduced LVEF in the 43\u201346% range for more than three years prior to therapy but achieved sustained improvement by 12 months (NYHA III to II, LVEF 43% to 64%, 6MWT 265 to 380\u00a0m).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our preliminary findings suggest the safety and feasibility of intracoronary transplantation of allogeneic WJ-MSCs in PDCM, with potential off-the-shelf therapeutic benefit. Validation of these observations in larger randomized controlled trials is needed to better evaluate long-term safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05866-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:24:27Z","timestamp":1777292667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A HEART-WISE: Allogeneic Wharton\u2019s Jelly-derived Mesenchymal Stromal Cells\u2019 Intracoronary Transplantation in Pediatric Patients with Dilated Cardiomyopathy: The First Case Reports"],"prefix":"10.1186","volume":"26","author":[{"given":"Hoda","family":"Madani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pahlavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Barekat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara","family":"Rezaei-kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Aghdami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Akbar","family":"Zeinaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"5866_CR1","doi-asserted-by":"crossref","unstructured":"Malinow I, Fong DC, Miyamoto M, Badran S, Hong CC. Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis. Front Pediatr. 2024;12:1404942.","DOI":"10.3389\/fped.2024.1404942"},{"key":"5866_CR2","first-page":"1","volume":"15","author":"SM Selem","year":"2013","unstructured":"Selem SM, Kaushal S, Hare JM. Stem cell therapy for pediatric dilated cardiomyopathy. Curr Cardiol Rep 2013;15(6):369.","journal-title":"Stem cell therapy Pediatr dilated cardiomyopathy"},{"key":"5866_CR3","unstructured":"LIU G, DU Z. Advance of mesenchymal stem cells in the treatment of cardiovascular diseases in children. Int J Pediatr. 2020:5\u20138."},{"key":"5866_CR4","first-page":"6","volume":"5","author":"Y Alzghoul","year":"2024","unstructured":"Alzghoul Y, Hala J, Sanajleh A, Alabduh T, Rababah F, Al-Shdaifat M, et al. Therapeutic and regenerative potential of different sources of mesenchymal stem cells for cardiovascular diseases. Biocell. 2024;48(4):559.","journal-title":"Therapeutic regenerative potential different sources mesenchymal stem cells Cardiovasc Dis"},{"key":"5866_CR5","doi-asserted-by":"crossref","unstructured":"Liau LL, Ruszymah BH, Ng MH, Law JX. Characteristics and clinical applications of Wharton\u2019s jelly-derived mesenchymal stromal cells. Curr Res Transl Med. 2020;68(1):5\u201316.","DOI":"10.1016\/j.retram.2019.09.001"},{"key":"5866_CR6","doi-asserted-by":"crossref","unstructured":"Arki MK, Moeinabadi-Bidgoli K, Niknam B, Mohammadi P, Hassan M, Hossein-Khannazer N, et al. Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources. Heliyon. 2024;10(2):e24948.","DOI":"10.1016\/j.heliyon.2024.e24948"},{"key":"5866_CR7","doi-asserted-by":"crossref","unstructured":"Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, et al. Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study) A phase I\/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cell vs. Allogeneic Mesenchymal Stem Cells in Patients with Non-ischemic Dilated Cardiomyopathy. J Cardiovasc Transl Res. 2014;7(9):769\u201380.","DOI":"10.1007\/s12265-014-9594-0"},{"key":"5866_CR8","doi-asserted-by":"crossref","unstructured":"Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69(5):526\u201337.","DOI":"10.1016\/j.jacc.2016.11.009"},{"key":"5866_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s12265-014-9594-0","volume":"7","author":"M Mushtaq","year":"2014","unstructured":"Greene SJ, Epstein SE, Kim RJ, Quyyumi AA, Cole RT, Anderson AS, et al. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. J Cardiovasc Med. 2017;18(4):283\u201390.","journal-title":"J Cardiovasc Transl Res"},{"issue":"5","key":"5866_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","volume":"69","author":"JM Hare","year":"2017","unstructured":"Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, et al. A Phase I Study of Allogeneic Mesenchymal Stem Cell Therapy in Patients with Heart Failure Secondary to Anthracycline-induced Cardiomyopathy: the cctrn stem cell injection in cancer survivors (Seneca) trial. J Card Fail. 2020;26(10):S97.","journal-title":"J Am Coll Cardiol"},{"key":"5866_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02165-4","volume":"12","author":"S-MR Hashemian","year":"2021","unstructured":"Hashemian SM, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res therapy. 2021;12(1):91.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5866_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici ML, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"7","key":"5866_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3109\/14653249.2011.574118","volume":"13","author":"S-P Chin","year":"2011","unstructured":"Chin SP, Poey AC, Wong CY, Chang SK, Tan CS, Ng MT, et al. Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy. Cytotherapy. 2011;13(7):814\u201321.","journal-title":"Cytotherapy"},{"key":"5866_CR14","doi-asserted-by":"crossref","unstructured":"Hare JM, Fishman JE, Gerstenblith G, Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Jama. 2012;308(22):23697\u20139.","DOI":"10.1001\/jama.2012.25321"},{"issue":"11","key":"5866_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","volume":"121","author":"V Florea","year":"2017","unstructured":"Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, et al. Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (the TRIDENT study). Circ Res. 2017;121(11):1279\u201390.","journal-title":"Circul Res"},{"key":"5866_CR16","doi-asserted-by":"crossref","unstructured":"Bartolucci J, Verdugo FJ, Gonz\u00e1lez PL, Larrea RE, Abarzua E, Goset, C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circulation research. 2017;121(10):1192\u2013204.","DOI":"10.1161\/CIRCRESAHA.117.310712"},{"issue":"8","key":"5866_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/1574888X16666210816111031","volume":"17","author":"J Yu","year":"2022","unstructured":"Yu J, Zhang RF, Mao YL, Zhang H. Efficacy and safety of mesenchymal stem cell therapy in patients with acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Stem Cell Res Ther. 2022;17(8):793\u2013807.","journal-title":"Curr Stem Cell Res Therapy"},{"key":"5866_CR18","doi-asserted-by":"crossref","unstructured":"Zeinaloo A, Zanjani KS, Bagheri MM, Mohyeddin\u2010Bonab M, Monajemzadeh M, Arjmandnia MH. Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatric transplantation. 2011;15(8):E183\u20136.","DOI":"10.1111\/j.1399-3046.2010.01366.x"},{"key":"5866_CR19","doi-asserted-by":"crossref","unstructured":"Limsuwan A, Pienvichit P, Limpijankit T, Khowsathit P, Hongeng S, Pornkul R, et al. Transcoronary bone marrow\u2010derived progenitor cells in a child with myocardial infarction: first pediatric experience. Clin Cardiol. 2010;33(8):E7\u201312.","DOI":"10.1002\/clc.20463"},{"key":"5866_CR20","doi-asserted-by":"crossref","unstructured":"Zschirnt M, Jux C, Boenig H, Zeiher A, Assmus B, Khalil M, et al. Neonatal myocardial infarction: substantial improvement of cardiac function after autologous bone marrow-derived cell therapy. Clin Res Cardiol. 2019;108(11):1309\u201311.","DOI":"10.1007\/s00392-019-01478-y"},{"key":"5866_CR21","doi-asserted-by":"crossref","unstructured":"Rupp S, Bauer J, Tonn T, Sch\u00e4chinger V, Dimmeler S, Zeiher AM, et al. Intracoronary administration of autologous bone marrow\u2010derived progenitor cells in a critically ill two\u2010yr\u2010old child with dilated cardiomyopathy. Pediatr Transplant. 2009;13(5):620\u20133.","DOI":"10.1111\/j.1399-3046.2008.01024.x"},{"key":"5866_CR22","doi-asserted-by":"crossref","unstructured":"Olgunt\u00fcrk R, Kula S, Sucak GT, \u00d6zdo\u011fan ME, Erer D, Saygili A. Peripheric stem cell transplantation in children with dilated cardiomyopathy: preliminary report of first two cases. Pediatr Transplant. 2010;14(2):257\u201360.","DOI":"10.1111\/j.1399-3046.2009.01215.x"},{"key":"5866_CR23","doi-asserted-by":"crossref","unstructured":"Lacis A, Erglis A. Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiol Young. 2011;21(1):110\u20132.","DOI":"10.1017\/S1047951110001435"},{"key":"5866_CR24","doi-asserted-by":"crossref","unstructured":"Rivas J, Men\u00e9ndez JJ, Arrieta R, Alves J, Romero MP, Garc\u00eda-Guereta L, et al. Usefulness of intracoronary therapy with progenitor cells in patients with dilated cardiomyopathy: bridge or alternative to heart transplantation?. InAnales de Pediatria (Barcelona, Spain: 2003). 2011;74(4):218\u201325.","DOI":"10.1016\/j.anpedi.2011.02.013"},{"key":"5866_CR25","doi-asserted-by":"crossref","unstructured":"Rupp S, Jux C, B\u00f6nig H, Bauer J, Tonn T, Seifried E, et al. Intracoronary bone marrow cell application for terminal heart failure in children. Cardiol Young. 2012;22(5):558\u201363.","DOI":"10.1017\/S1047951112000066"},{"issue":"3","key":"5866_CR26","first-page":"266","volume":"17","author":"I Bergmane","year":"2013","unstructured":"Bergmane I, Lacis A, Lubaua I, Jakobsons E, Erglis A. Follow\u2010up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatr Transplant. 2013;17(3):266\u201370.","journal-title":"Follow-up patients after stem cell transplantation Pediatr dilated cardiomyopathy"},{"key":"5866_CR27","doi-asserted-by":"crossref","unstructured":"Pincott ES, Ridout D, Brocklesby M, McEwan A, Muthurangu V, Burch M. A randomized study of autologous bone marrow\u2013derived stem cells in pediatric cardiomyopathy. J Heart Lung Transplant. 2017;36(8):837\u201344.","DOI":"10.1016\/j.healun.2017.01.008"},{"key":"5866_CR28","doi-asserted-by":"crossref","unstructured":"Amoozgar H, Edraki MR, Ayatollahi M, Borzouee M, Ajami G, Mohammadi H, et al. A study of intracoronary injection of hematopoietic stem cells in pediatric dilated cardiomyopathy: is it an applicable solution for critically Ill patients. Iranian J Pediatr. 2019;29(3):e83408.","DOI":"10.5812\/ijp.83408"},{"key":"5866_CR29","doi-asserted-by":"crossref","unstructured":"Hirai K, Ousaka D, Fukushima Y, Kondo M, Eitoku T, Shigemitsu Y, et al. Cardiosphere-derived exosomal microRNAs for myocardial repair in pediatric dilated cardiomyopathy. Sci Transl Med. 2020;12(573):eabb3336.","DOI":"10.1126\/scitranslmed.abb3336"},{"issue":"1","key":"5866_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-024-03713-4","volume":"15","author":"ZT Ahmed","year":"2024","unstructured":"Ahmed ZT, Zain Al-Abeden MS, Al Abdin MG, Muqresh MA, Al Jowf GI, Eijssen LM, et al. Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs. Stem Cell Res Ther. 2024;15(1):165.","journal-title":"Stem Cell Res Ther"},{"key":"5866_CR31","doi-asserted-by":"publisher","first-page":"p1065","DOI":"10.12688\/f1000research.153131.1","volume":"13","author":"S Tello Vera","year":"2024","unstructured":"Tello Vera S, Failoc Rojas VE, Le\u00f3n Trujillo FJ. Effect of the dose, timing, and route of administration of mesenchymal stem cells on their regenerative capacity after myocardial infarction: a systematic review. F1000Research. 2024;13:1065.","journal-title":"F1000Research"},{"issue":"1","key":"5866_CR32","first-page":"1","volume":"6","author":"M Banovic","year":"2015","unstructured":"Banovic M, Loncar Z, Behfar A, Vanderheyden M, Beleslin B, Zeiher A, et al. Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res Ther. 2015;6(1):159.","journal-title":"Endpoints stem cell trials ischemic heart Fail"},{"key":"5866_CR33","doi-asserted-by":"crossref","unstructured":"Dorobantu M, Popa-Fotea NM, Popa M, Rusu I, Micheu MM. Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease. World J Stem Cells. 2017;9(12):203.","DOI":"10.4252\/wjsc.v9.i12.203"},{"key":"5866_CR34","doi-asserted-by":"crossref","unstructured":"Marquis-Gravel G, Stevens LM, Mansour S, Avram R, Noiseux N. Stem cell therapy for the treatment of nonischemic cardiomyopathy: a systematic review of the literature and meta-analysis of randomized controlled trials. Can J Cardiol. 2014;30(11):1378\u201384.","DOI":"10.1016\/j.cjca.2014.03.026"},{"key":"5866_CR35","doi-asserted-by":"crossref","unstructured":"Poulin MF, Deka A, Mohamedali B, Schaer GL. Clinical benefits of stem cells for chronic symptomatic systolic heart failure: a systematic review of the existing data and ongoing trials. Cell transplantation. 2016;25(11):1911\u201323.","DOI":"10.3727\/096368916X692087"},{"issue":"3","key":"5866_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201371.","journal-title":"Eur Heart Journal-Cardiovascular Imaging"},{"issue":"16","key":"5866_CR37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","volume":"21","author":"NG Bellenger","year":"2000","unstructured":"Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable?. Eur Heart J. 2000;21(16):1387\u201396.","journal-title":"Eur Heart J"},{"issue":"1","key":"5866_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","volume":"90","author":"F Grothues","year":"2002","unstructured":"Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90(1):29\u201334.","journal-title":"Am J Cardiol"},{"issue":"3","key":"5866_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nature biotechnology. 2014;32(3):252\u201360.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"5866_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcyt.2018.01.009","volume":"20","author":"K Le Blanc","year":"2018","unstructured":"Le Blanc K, Davies LC. MSCs\u2014cells with many sides. Cytotherapy. 2018;20(3):273\u20138.","journal-title":"Cytotherapy"},{"issue":"5","key":"5866_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/CIRCRESAHA.118.312823","volume":"123","author":"F Fern\u00e1ndez-Avil\u00e9s","year":"2018","unstructured":"Fern\u00e1ndez-Avil\u00e9s F, Sanz-Ruiz R, Bogaert J, Casado Plasencia A, Gilaberte I, Belmans A, et al. Safety and efficacy of intracoronary infusion of allogeneic human cardiac stem cells in patients with ST-segment elevation myocardial infarction and left ventricular dysfunction: a multicenter randomized, double-blind, and placebo-controlled clinical trial. Circ Res. 2018;123(5):579\u201389.","journal-title":"Circul Res"},{"key":"5866_CR42","doi-asserted-by":"crossref","unstructured":"Thompson M, Mei SH, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. Clin Med. 2020;19:100249.","DOI":"10.1016\/j.eclinm.2019.100249"},{"issue":"13","key":"5866_CR43","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/jcm10132991","volume":"10","author":"R Sanabria-de la Torre","year":"2021","unstructured":"Sanabria-de la Torre R, Qui\u00f1ones-Vico MI, Fernandez-Gonzalez A, Sanchez-Diaz M, Montero-Vilchez T, Sierra-Sanchez A, et al. Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review. J Clin Med. 2021;10(13):2991.","journal-title":"J Clin Med"},{"key":"5866_CR44","doi-asserted-by":"crossref","unstructured":"Shahzad MA, Ishtiaq R, Zahid U, Anwer F. Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors. Case Rep. 2016;2016:bcr2016217210.","DOI":"10.1136\/bcr-2016-217210"},{"key":"5866_CR45","doi-asserted-by":"crossref","unstructured":"Abushouk AI, Salem AM, Saad A, Afifi AM, Afify AY, Afify H, et al. Mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy: potential mechanisms, governing factors, and implications of the heart stem cell debate. Front Pharmacol. 2019;10:635.","DOI":"10.3389\/fphar.2019.00635"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05866-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:48:27Z","timestamp":1781650107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05866-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5866"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05866-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The title of the approved study is \u201cWharton\u2019s Jelly Derived-Mesenchymal Stem Cells Transplantation in Pediatric Patients with Non-Ischemic Dilated Cardiomyopathy.\u201d The ethics committee\/institution that approved the study is the Ethics Committee of Tehran University of Medical Sciences. The ethics approval reference number for the study is IR.TUMS.MEDICINE.REC.1399.896, and the date the ethics approval was granted is 2020-12-13.The study trial registration: IRCT, IRCT20201217049743N1 was registered 29 January 2021,\n                      \n                      , adhering to the principles of the \u201cDeclaration of Helsinki.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"509"}}